Please login to the form below
skin cancer
This page shows the latest skin cancer news and features for those working in and with pharma, biotech and healthcare.
ICR research shows how skin cancer cells invade new tissues
Targeting a specific gene could lead to treatments that prevent cancer from spreading. ... Melanoma skin cancer cells harness a gene – usually used to create connections between nerves – to escape from their immediate area and invade new tissues,
Latest news
-
Sanofi and Innovent Biologics to develop oncology drugs for patients in China
SAR444245 is a potential first-in-class reprogrammed, site-directed, single PEGylated, recombinant human IL-2 (rIL-2) variant that is currently under global phase 2 studies for skin cancers, gastrointestinal ... s safety and effectiveness in a wide
-
Bristol Myers Squibb’s Opdualag approved by CHMP for melanoma
Melanoma is a type of skin cancer distinguished by the uncontrolled growth of melanocytes – pigment-producing cells – located in the skin. ... It is the deadliest form of the disease, occurring when cancer spreads past the skin’s surface to other
-
Almirall launches call on AlmirallShare to find innovative therapies for skin diseases
The assets may also be suitable for non-melanoma skin cancer such as basal and squamous cell carcinoma and cutaneous T cell lymphoma, or rare dermatological indications such as epidermolysis bullosa,
-
EORTC and Pierre Fabre launch phase 3 trial for melanoma
The European Organisation for Research and Treatment of Cancer (EORTC) and health and beauty care company, Pierre Fabre, have begun a phase 3 study to assess a combination therapy for patients ... Melanoma develops through unrepaired DNA damage to skin
-
NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC
As the second most common skin cancer in the UK, CSCC accounts for 23% of all non-melanoma skin cancers. ... Diagnoses of non-melanoma skin cancer are increasing and have been forecast to continue until 2040.
More from news
Approximately 23 fully matching, plus 137 partially matching documents found.
Latest Intelligence
-
Encouraging signs in biomarker R&D
For example, skin cancer patients who carry a BRAF V600 mutation are more likely to respond to BRAF inhibitors like Roche’s Zelboraf (Vemurafenib) than people without such mutations. ... He also cited an FDA-approved TMB test developed by Foundation
-
Digital health
What digital health has delivered to date is amazing. The examples are legion: an application which can differentially diagnose lesions on skin with 20-30 times more accuracy than a doctor ... when it comes to skin cancer, or HealthTap’s Dr AI which
-
Case study: Skin cancer awareness
Skin cancer is on the increase. It is one of the most common cancers in the 15-24 age group and a significant cause of death. ... Posters and leaflets do not get through to younger people; at this age they feel invincible and believe skin cancer will
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
CytomX appoints Rachel Humphrey chief medical officer
Before her time at AZ and Eli Lilly, Humphrey was also VP of product development at Bristol-Myers Squibb where she led all aspects of clinical development of the skin-cancer
-
Kite Pharma appoints Zelboraf scientist as CMO
Keith Nolop joins US cancer biotech from Plexxikon. Dr Keith Nolop, one of the chief scientists behind the development of Roche's personalised skin cancer drug Zelboraf, has been appointed chief ... At Plexxikon, he also led the filing of eight
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
The heavy toll of COVID-19 on cancer patients
During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. ... The rate of skin cancer diagnosis dropped the most. In Italy, cancer diagnoses fell by 39% during lockdown, compared to the two previous years.
-
University spin-out fund makes half a million pound first investments
One of the first businesses to receive investment was AMLo Biosciences, a Newcastle University spin-out developing diagnostics for early-stage skin cancer.
-
Using Healthtech to Deliver Better Patient Outcomes
Peter Birch, General Manager (Asia Pacific) at MetaOptima Technologies &host of the “ Talking HealthTech Podcast.” joins us to discuss a whole range of topics, including Peter’s professional journey and the work he is doing with the
-
If our patients are diverse, why are clinical trials so white?
How many times have you been told to put on sunscreen to prevent skin cancer? ... https://www.cdc.gov/cancer/skin/statistics/behavior/sunprotection. htm. https://www.ncbi.nlm.nih.gov/pubmed/15837865. https://www.sciencedirect.com/science/article/pii/
-
Battling breast cancer with precision medicine (Part 1)
I was diagnosed with inflammatory breast cancer (IBC) with axillary lymph node involvement, including supraclavicular nodes. ... The cancer cells attack the skin and lymph vessels around the breast, and about 5, 000 cases are diagnosed every year in the
More from PMHub
Approximately 2 fully matching, plus 7 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
